Heart and Neural Crest Derivatives Expressed Transcript 2 (HAND2)

Buell-Gutbrod, Rebecca; Cavallo, Allison; Lee, Nita; Montag, Anthony; Gwin, Katja

doi:10.1097/pgp.0000000000000106

Cited by 18 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 25 ] The continuous proliferation of the endometrium was observed in mice with knockdown of HAND2. [ 26 ] Here, bioinformatic results showed that the downregulation of HAND2 was potentially regulated by hypermethylation, which was first reported in colon cancer.…”

Section: Discussionmentioning

confidence: 90%

Identification of regulatory role of DNA methylation in colon cancer gene expression via systematic bioinformatics analysis

Yang

Chu

et al. 2017

Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 90%

Identification of regulatory role of DNA methylation in colon cancer gene expression via systematic bioinformatics analysis

Yang

Chu

et al. 2017

Medicine

View full text Add to dashboard Cite

show abstract

“…HAND2 was negatively regulated by mir-1-2 (Fig 3), which is down-regulated in READ with increased methylation. It is related to endometrial carcinoma, non-small cell lung cancer and neuroblastoma [35–37]. HAND2 is absent in endometrioid carcinoma and reduced in atypical hyperplasia compared to benign endometrium; knockout of HAND2 leads to continuous proliferation in mice model [35].…”

Section: Discussionmentioning

confidence: 99%

“…It is related to endometrial carcinoma, non-small cell lung cancer and neuroblastoma [35–37]. HAND2 is absent in endometrioid carcinoma and reduced in atypical hyperplasia compared to benign endometrium; knockout of HAND2 leads to continuous proliferation in mice model [35]. HAND2, as the transcript factor, is over-expressed in early stage of lung squamous cell carcinoma instead of lung adenocarcinoma [36].…”

Section: Discussionmentioning

confidence: 99%

Abnormal expression of mRNA, microRNA alteration and aberrant DNA methylation patterns in rectal adenocarcinoma

Yang

Liu

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

AimRectal adenocarcinoma (READ) is a malignancy cancer with the high morbidity and motility worldwide. Our study aimed to explore the potential pathogenesis of READ through integrated analysis of gene expression profiling and DNA methylation data.MethodsThe miRNA, mRNA expression profiling and corresponding DNA methylation data were downloaded from The Cancer Genome Atlas (TCGA) database. Differentially expressed mRNAs/ miRNAs/methylated regions (DEmRNA/DEmiRNAs) were identified in READ. The negatively correlation of DEmiRNA-DEmRNAs and DNA methylation-DEmRNAs were obtained. DEmRNAs expression was validated through quantitative real-time polymerase chain reaction (qRT-PCR) and microarray expression profiling analyses.Results1192 dysregulated DEmRNAs, 27 dysregulated DEmiRNAs and 6403 aberrant methylation CpG sites were screened in READ compared to normal controls. 1987 negative interaction pairs among 27 DEmiRNAs and 668 DEmRNAs were predicted. 446 genes with aberrant methylation were annotated. Eventually, 50 DEmRNAs (39 down- and 11 up-regulated DEmRNAs) with hypermethylation, synchronously negatively targeted by DEmiRNAs, were identified through the correlation analysis among 446 genes with aberrant methylation and 668 DEmRNAs. 50 DEmRNAs were significantly enriched in cAMP signaling pathway, circadian entrainment and glutamatergic synapse. The validation results of expression levels of DEmRNAs through qRT-PCR and microarray analyses were compatible with our study.Conclusion7 genes of SORCS1, PDZRN4, LONRF2, CNGA3, HAND2, RSPO2 and GNAO1 with hypermethylation and negatively regulation by DEmiRNAs might contribute to the tumorigenesis of READ. Our work might provide valuable foundation for the READ in mechanism elucidation, early diagnosis and therapeutic target identification.

show abstract

“… Buell-Gutbrod et al . (2015) also hypothesized that HAND2 plays a role in the development of EH and Type 1 endometrioid EC ( Supplementary Table SI ).…”

Section: Immunohistochemical Biomarkers For Diagnosis Of Endometrial mentioning

confidence: 99%

New concepts for an old problem: the diagnosis of endometrial hyperplasia

Sanderson

Critchley

Williams

et al. 2016

Hum. Reprod. Update

216

244

View full text Add to dashboard Cite

BACKGROUNDEndometrial hyperplasia (EH) is a uterine pathology representing a spectrum of morphological endometrial alterations. It is predominantly characterized by an increase in the endometrial gland-to-stroma ratio when compared to normal proliferative endometrium. The clinical significance of EH lies in the associated risk of progression to endometrioid endometrial cancer (EC) and ‘atypical’ forms of EH are regarded as premalignant lesions. Traditional histopathological classification systems for EH exhibit wide and varying degrees of diagnostic reproducibility and, as a consequence, standardized patient management can be challenging.OBJECTIVE AND RATIONALEEC is the most common gynaecological malignancy in developed countries. The incidence of EC is rising, with alarming increases described in the 40–44-year-old age group. This review appraises the current EH classification systems used to stratify women at risk of malignant progression to EC. In addition, we summarize the evidence base regarding the use of immunohistochemical biomarkers for EH and discuss an emerging role for genomic analysis.SEARCH METHODSPubMed, Medline and the Cochrane Database were searched for original peer-reviewed primary and review articles, from January 2000 to January 2016. The following search terms were used: ‘endometrial hyperplasia’, ‘endometrial intraepithelial neoplasia’, ‘atypical hyperplasia’, ‘complex atypical hyperplasia’, ‘biomarker’, ‘immunohistochemistry’, ‘progression’, ‘genomic’, ‘classification’ and ‘stratification’.OUTCOMESRecent changes to EH classification reflect our current understanding of the genesis of endometrioid ECs. The concept of endometrial intraepithelial neoplasia (EIN) as a mutationally activated, monoclonal pre-malignancy represents a fundamental shift from the previously held notion that unopposed oestrogenic stimulation causes ever-increasing hyperplastic proliferation, with accumulating cytological atypia that imperceptibly leads to the development of endometrioid EC. Our review highlights several key biomarker candidates that have been described as both diagnostic tools for EH and markers of progression to EC. We propose that, moving forwards, a ‘panel’ approach of combinations of the immunohistochemical biomarkers described in this review may be more informative since no single candidate can currently fill the entire role.WIDER IMPLICATIONSEC has historically been considered a predominantly postmenopausal disease. Owing in part to the current unprecedented rates of obesity, we are starting to see signs of a shift towards a rising incidence of EC amongst pre- and peri-menopausal woman. This creates unique challenges both diagnostically and therapeutically. Furthering our understanding of the premalignant stages of EC development will allow us to pursue earlier diagnosis and facilitate appropriate stratification of women at risk of developing EC, permitting timely and appropriate therapeutic interventions.

show abstract

Heart and Neural Crest Derivatives Expressed Transcript 2 (HAND2)

Cited by 18 publications

References 0 publications

Identification of regulatory role of DNA methylation in colon cancer gene expression via systematic bioinformatics analysis

Identification of regulatory role of DNA methylation in colon cancer gene expression via systematic bioinformatics analysis

Abnormal expression of mRNA, microRNA alteration and aberrant DNA methylation patterns in rectal adenocarcinoma

New concepts for an old problem: the diagnosis of endometrial hyperplasia

Contact Info

Product

Resources

About